Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CORBF
Global Cord Blood
$1.26
+5.0%
$0.99
$0.25
$2.00
$145.86M-0.66128,767 shs2,765 shs
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$18.91
+2.0%
$18.27
$15.45
$35.84
$535.29M1.03419,688 shs335,521 shs
Enhabit, Inc. stock logo
EHAB
Enhabit
$9.34
-2.5%
$9.31
$6.85
$10.91
$485.11M1.8461,608 shs312,067 shs
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
$5.45
-0.2%
$5.21
$3.97
$28.41
$494.13M1.591.88 million shs1.95 million shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CORBF
Global Cord Blood
+5.00%+0.80%+20.00%+57.50%+5.00%
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
+2.00%+2.55%+15.30%-5.78%-14.67%
Enhabit, Inc. stock logo
EHAB
Enhabit
-2.59%-8.61%-11.95%+0.51%+7.63%
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
-0.18%+0.37%+22.47%-37.86%-76.65%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CORBF
Global Cord Blood
N/AN/AN/AN/AN/AN/AN/AN/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
2.4609 of 5 stars
3.53.00.00.01.92.50.0
Enhabit, Inc. stock logo
EHAB
Enhabit
1.3016 of 5 stars
1.03.00.00.02.50.02.5
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
3.8984 of 5 stars
3.91.00.00.02.80.83.8
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CORBF
Global Cord Blood
0.00
N/AN/AN/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
3.00
Buy$37.0095.66% Upside
Enhabit, Inc. stock logo
EHAB
Enhabit
2.00
Hold$8.50-9.01% Downside
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
1.86
Reduce$15.00175.23% Upside

Current Analyst Ratings Breakdown

Latest CORBF, CSTL, FTRE, and EHAB Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
5/21/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$44.00 ➝ $40.00
5/14/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/14/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$10.00 ➝ $8.00
5/14/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$7.00 ➝ $5.00
5/13/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$6.00 ➝ $5.00
5/6/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Lake Street Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$40.00 ➝ $35.00
5/6/2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$42.00 ➝ $37.00
5/2/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageHold$7.00
4/10/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Underweight$12.00 ➝ $6.00
4/9/2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$12.00 ➝ $10.00
(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CORBF
Global Cord Blood
$196.12M0.78$0.90 per share1.40N/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$332.07M1.64$1.00 per share18.84$16.28 per share1.16
Enhabit, Inc. stock logo
EHAB
Enhabit
$1.03B0.46$3.99 per share2.34$10.92 per share0.86
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
$2.70B0.18$1.57 per share3.47$15.19 per share0.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CORBF
Global Cord Blood
$79.04MN/A0.00N/AN/AN/AN/AN/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
$18.25M-$0.19N/AN/AN/A-1.46%3.41%2.95%8/4/2025 (Estimated)
Enhabit, Inc. stock logo
EHAB
Enhabit
-$156.20M-$2.77N/A32.21N/A-13.43%2.02%0.94%8/5/2025 (Estimated)
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
-$328.50M-$8.79N/A4.260.37-29.43%2.84%1.06%8/11/2025 (Estimated)

Latest CORBF, CSTL, FTRE, and EHAB Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
-$0.07$0.02+$0.09-$6.25$609.63 million$651.30 million
5/7/2025Q1 2025
Enhabit, Inc. stock logo
EHAB
Enhabit
$0.07$0.10+$0.03$0.35$266.11 million$259.90 million
5/5/2025Q1 2025
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
-$0.08-$0.20-$0.12-$0.90$80.40 million$87.99 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CORBF
Global Cord Blood
N/AN/AN/AN/AN/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
N/AN/AN/AN/AN/A
Enhabit, Inc. stock logo
EHAB
Enhabit
N/AN/AN/AN/AN/A
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CORBF
Global Cord Blood
N/AN/AN/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
0.02
9.37
9.19
Enhabit, Inc. stock logo
EHAB
Enhabit
0.82
1.49
1.49
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
1.22
0.97
0.97

Institutional Ownership

CompanyInstitutional Ownership
CORBF
Global Cord Blood
N/A
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
92.60%
Enhabit, Inc. stock logo
EHAB
Enhabit
N/A
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
N/A

Insider Ownership

CompanyInsider Ownership
CORBF
Global Cord Blood
0.50%
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
6.50%
Enhabit, Inc. stock logo
EHAB
Enhabit
3.40%
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
0.38%
CompanyEmployeesShares OutstandingFree FloatOptionable
CORBF
Global Cord Blood
1,200121.55 millionN/ANot Optionable
Castle Biosciences, Inc. stock logo
CSTL
Castle Biosciences
54028.87 million27.00 millionOptionable
Enhabit, Inc. stock logo
EHAB
Enhabit
10,70050.64 million48.92 millionOptionable
Fortrea Holdings Inc. stock logo
FTRE
Fortrea
15,50090.50 million90.16 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Global Cord Blood NYSE:CORBF

$1.26 +0.06 (+5.00%)
As of 06/18/2025 10:33 AM Eastern

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2022, it operated three cord blood banks, including one in the Beijing municipality; one in the Guangdong province; and one in the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation operates as a subsidiary of Blue Ocean Structure Investment Company Ltd.

Castle Biosciences stock logo

Castle Biosciences NASDAQ:CSTL

$18.91 +0.37 (+2.00%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$18.90 -0.01 (-0.05%)
As of 06/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.

Enhabit stock logo

Enhabit NYSE:EHAB

$9.34 -0.24 (-2.48%)
Closing price 06/18/2025 03:59 PM Eastern
Extended Trading
$9.35 +0.01 (+0.09%)
As of 06/18/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enhabit, Inc. provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services. The company offers hospice services, including pain and symptom management, palliative and dietary counseling, social worker visits, spiritual counseling, and bereavement counseling services to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is based in Dallas, Texas.

Fortrea stock logo

Fortrea NASDAQ:FTRE

$5.45 -0.01 (-0.18%)
Closing price 06/18/2025 04:00 PM Eastern
Extended Trading
$5.45 0.00 (0.00%)
As of 06/18/2025 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services, as well as consulting services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.